1312
MULTIPLEX BIOMARKER SERUM ASSAY DETECTS EARLY PANCREATIC ADENOCARCINOMA IN HIGH-RISK PATIENTS
Date
May 21, 2024
Tracks
Related Products
POST-ERCP PANCREATITIS IN PERIAMPULLARY MALIGNANCIES – A HARBINGER FOR POST-OPERATIVE COMPLICATIONS AND PANCREATIC FISTULAS
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
ENDOSCOPIC ULTRASOUND (EUS) BETTER PREDICTS TUMOR SIZE AND VASCULAR INVOLVEMENT COMPARED TO CROSS-SECTIONAL IMAGING IN PANCREATIC CANCER
BACKGROUND: Accurate clinical staging plays a key role in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC)…
SURVIVAL BENEFIT OF NEOADJUVANT CHEMOTHERAPY IN RESECTABLE PANCREATIC CANCER – NEED BOTH ENDS OF THE SANDWICH
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
GOBLET CELL ADENOCARCINOMA AND RESPONSE TO TREATMENT - SINGLE CENTER EXPERIENCE OF A RARE MALIGNANCY
Goblet cell adenocarcinoma is a rare malignancy with an incidence of 1 per 2 million people worldwide…